BridgeMD
New treatment option for Leukemia
Official title Early Integration of Palliative and Supportive Care in Cellular Therapy
ClinicalTrials.gov ID: NCT05190653
What this study is testing
- What it's testing
- Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved survival. Yet, in spite of the proven benefits of integration of palliative care in oncology, it has been well established that patients with hematologic malignancies and those undergoing cellular therapy (hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy) do not routinely receive palliative care.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients
- Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
- Ability to speak, read, and understand English or, be able to complete questionnaires with minimal assistance required from an interpreter
- Family Caregivers
- Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric...
You likely can't join if
- Patients
- Patients undergoing HSCT for a non-malignant hematologic condition
- Inability to provide informed consent Exclusion Criterion - Family Caregivers \ Inability to provide informed consent
See the full eligibility criteria
- Patients
- Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
- Ability to speak, read, and understand English or, be able to complete questionnaires with minimal assistance required from an interpreter
- Family Caregivers
- Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
- A spouse, relative, or friend, identified by the patient, who either lives with the patient or has in-person contact with the patient at least twice per week. Only one family CG per patient will be asked to participate.
- Ability to speak, read, and understand English or willing to complete questionnaires with minimal assistance required from an interpreter
- Patients
- Patients undergoing HSCT for a non-malignant hematologic condition
- Inability to provide informed consent Exclusion Criterion - Family Caregivers \ Inability to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Calgary, Alberta, Canada
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calgary, Alberta, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.